Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO-7847 Phase 3 Study, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7847 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Patients with Malignant Tumor.

Next Previous
Trial Profile

ONO-7847 Phase 3 Study, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7847 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Patients with Malignant Tumor.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical

Most Recent Events

  • 11 Dec 2012 New trial record
  • 31 Oct 2012 Results published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top